Zura Bio Limited - ZURA STOCK NEWS

Zura Bio, a clinical-stage immunology company (NASDAQ: ZURA), has announced an exchange offer and consent solicitation for its public and private placement warrants issued during its initial public offering. The company aims to simplify its capital structure and reduce potential dilution by offering 0.30 Class A ordinary shares for each outstanding IPO warrant. This exchange offer could result in issuing up to 3,842,999 new shares, an approximate 6% increase in outstanding shares. Concurrently, Zura Bio seeks consents to amend the warrant agreement to enforce the exchange of all remaining warrants at 0.27 shares per warrant if the offer succeeds. The offer period ends on August 8, 2024. Parties holding 40.7% of public warrants and 65.3% of private placement warrants have already agreed to tender their warrants.

Zura Bio presented data on tibulizumab (ZB-106) at EULAR 2024, demonstrating promising results in treating Sjogren's syndrome and rheumatoid arthritis (RA). The Phase 1 study showed tibulizumab was well-tolerated and effective in neutralizing IL-17A and BAFF, reducing B cell counts and modulating inflammatory mediators in 25 participants. Preclinical data in a RA mouse model indicated significant reductions in disease scores and inflammation when both IL-17A and BAFF were inhibited. The studies suggest tibulizumab's potential as a dual-pathway treatment for autoimmune diseases.

Zura Bio, a clinical-stage immunology company, has formed a Scientific Advisory Board (SAB) with experts in rheumatology, dermatology, and immunology. The board includes Johann Gudjonsson, Dinesh Khanna, Ajay Nirula, Michael Weinblatt, and Steven Ziegler. This initiative aims to advance their clinical and translational science efforts, particularly in Phase 2 clinical development for systemic sclerosis and hidradenitis suppurativa. The SAB will also focus on the roles of BAFF and IL-17A in autoimmune and inflammatory diseases, enhancing Zura Bio's research and clinical trials.

Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to illustrate the antibody's capacity to inhibit both pathways in a single therapy, potentially broadening its clinical applications across various autoimmune diseases. Zura Bio also disclosed timelines for Phase 2 trials: systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025.

Zura Bio, a clinical-stage immunology company with a focus on novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced participation in two June investor conferences. Chief Scientific Officer Michael Howell will attend one-on-one meetings at the Jefferies Global Healthcare Conference on June 6, 2024, in New York. CEO Robert Lisicki will participate in a panel discussion on dermatological disorders and hold one-on-one meetings at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024, in New York. These events aim to strengthen investor relations and provide insights into Zura Bio's innovative clinical programs.

Zura Bio reported financial results for Q1 2024, ending with $89.8M in cash and closing an oversubscribed $112.5M private placement in April. The company appointed a new CEO and CMO and is on track to start Phase 2 studies for SSc and HS. Cash runway extended through 2027. R&D expenses decreased, while G&A expenses increased. Net loss reduced. Anticipated milestones include Phase 2 trials for ZB-106 and monitoring of ZB-168 and ZB-880.

Zura Bio, a clinical stage immunology company, announced an oversubscribed $112.5 million private placement led by Access Biotechnology and other institutional investors. The financing is expected to fund operations through 2027, supporting the development of tibulizumab for autoimmune diseases.

Zura Bio appoints Robert Lisicki as CEO and Director, succeeding Dr. Someit Sidhu. The company aims to establish itself as a leading immunology company with a focus on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.

Zura Bio (Nasdaq: ZURA) reported significant 2023 milestones, including a successful Nasdaq listing, a new CEO appointment, and a robust financial position. The company raised $145 million in 1H 2023, closed a Business Combination Agreement with JATT Acquisition Corp., and completed an $80 million financing round. Zura Bio's cash position as of December 31, 2023, stood at $99.8 million, supporting operations until 2026. The company plans to initiate a Phase 2 study for tibulizumab (ZB-106) in systemic sclerosis in 2H 2024, while also advancing ZB-168 and torudokimab towards Phase 2 readiness.